Single-domain antibodies as building blocks for novel therapeutics
about
Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domainBispecific antibodies for cancer therapy: the light at the end of the tunnel?The art of blocking ADP-ribosyltransferases (ARTs): nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTsPost-exposure Treatment with Anti-rabies VHH and Vaccine Significantly Improves Protection of Mice from Lethal Rabies InfectionStructural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH DomainsThe structural analysis of shark IgNAR antibodies reveals evolutionary principles of immunoglobulinsNanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infectionHeavy chain single-domain antibodies to detect native human soluble epoxide hydrolaseIsolation of alpaca anti-hapten heavy chain single domain antibodies for development of sensitive immunoassayHigh-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domainNovel camelid antibody fragments targeting recombinant nucleoprotein of Araucaria hantavirus: a prototype for an early diagnosis of Hantavirus Pulmonary SyndromeExtremophilic 50S Ribosomal RNA-Binding Protein L35Ae as a Basis for Engineering of an Alternative Protein ScaffoldLlama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral moleculesDerivative of Extremophilic 50S Ribosomal Protein L35Ae as an Alternative Protein ScaffoldEngineered human antibody constant domains with increased stability.A large human domain antibody library combining heavy and light chain CDR3 diversityEngineering of stable bispecific antibodies targeting IL-17A and IL-23.Engineered CH2 domains (nanoantibodies).Monitoring biodegradative enzymes with nanobodies raised in Camelus dromedarius with mixtures of catabolic proteins.Nanobodies to Study G Protein-Coupled Receptor Structure and Function.Identification and characterization of Nanobodies targeting the EphA4 receptor.Diagnostic evaluation of a nanobody with picomolar affinity toward the protease RgpB from Porphyromonas gingivalis.Modification of the loops in the ligand-binding site turns avidin into a steroid-binding protein.High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosisBacterial display in combinatorial protein engineering.Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.Engineered Fc based antibody domains and fragments as novel scaffolds.Detection of biomarkers using recombinant antibodies coupled to nanostructured platformsProtective effect of different anti-rabies virus VHH constructs against rabies disease in mice.Characterization and enzyme-conjugation of a specific anti-L1 nanobody.Peptide aptamers: development and applications.Assessing combinatorial strategies to multimerize libraries of single-domain antibodies.Isolation and optimization of camelid single-domain antibodies: Dirk Saerens' work on nanobodies.Strategies to stabilize compact folding and minimize aggregation of antibody-based fragmentsEngineered antibody variable and constant domains as therapeutic candidates.Characterization of camel nanobodies specific for superfolder GFP fusion proteins.Soluble monomeric IgG1 Fc.Algal chloroplast produced camelid VH H antitoxins are capable of neutralizing botulinum neurotoxin.Exploiting Nanobodies in the Detection and Quantification of Human Growth Hormone via Phage-Sandwich Enzyme-Linked Immunosorbent Assay.Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.
P2860
Q24634375-B3DA532B-D678-48E3-B15F-50B32DFAF73AQ24644083-D28A281E-8CE7-490A-8C37-4E324668BA99Q26991574-E4B4DAC9-F6ED-4F12-A014-B2BBB1191766Q27303580-7118E139-54C2-4F7C-9DEF-DEE741EB3546Q27678732-E96F21A1-5A9F-4B2D-BD62-885F0C741E96Q27683794-4A75B380-E4E5-4042-93BB-7D508C6AC5FDQ28308105-97BDC83F-DFC3-4641-AA02-336DFD863530Q28388884-313B4878-80AE-43C2-B8B5-5B20F263430AQ28395939-6D096EEA-4AEB-477F-BB50-2A94CBB330C0Q28480982-EFE56940-833B-4D82-9F1F-CA95DBAEAF7BQ28543136-C54C2059-9E2B-4A33-B843-D83A23ABB7EEQ28547051-AA02BB96-8D1E-4F37-808C-250FA7E0812CQ28741431-0DE65454-FE52-45C4-9E1A-84A6FB107C5FQ28818769-F0B14DFE-7730-455D-8965-CC66C32835FBQ33420655-D2E3E716-5686-473A-AF6F-C63A5956B952Q33514579-AD284E61-B555-403A-8F1E-A4B2E5D21E69Q33519833-14A7DFE7-4AB7-4C9C-B26D-87168148B4F6Q33521668-BA83BB15-118A-4669-940C-7BA6C4C8453DQ33789505-6C089C56-0AB8-482F-9CF8-ED61F9073667Q33880125-03AB3C03-4BFA-42DB-B591-56754AB01096Q33882055-31B4C365-AD61-4961-940A-E8B1CE56B0FAQ33899359-EE135616-A8E2-4323-9A09-75E6B2323331Q33928111-1B0B623F-893C-4606-8B49-93B25FCF7C05Q33941028-513E7869-B45E-4016-8B48-DD611746A955Q33970172-08BB9B1A-9865-42CF-8996-FC8BD27FD728Q34057785-C84EE6F6-C5F1-46AA-8EE4-AEBDA17D3215Q34289289-E3DECAF5-CA7E-4BA1-8C09-EFF9F93A517CQ34352221-2285D077-1E06-408B-A6B4-7BBBDD7A98FCQ34408085-DE1116E8-6292-40A6-9D1B-95C5148CEC9FQ34410377-E907DF2D-BD12-4322-A057-D5E55A671510Q34471346-8335D223-B4B5-49DC-9677-08080D3FE303Q34668664-3650434C-37F4-4859-B389-60944BE73615Q34878849-7ACB14D2-5737-4663-966E-B2DC6931FBBAQ35018813-CCB69809-5BFE-4D80-BA4A-3728DB784716Q35044156-BAB7CEF6-E802-4958-983D-98EF6A29F299Q35217452-02F9E24C-7C51-48F9-A0BA-B3BC8DFBECA4Q36003820-DC34BFAD-2337-4E31-9973-7F70CF6258F5Q36207498-C4963BD3-62E8-428F-BC1C-BE555CD2897EQ36404793-104923B5-0747-4E35-9B21-F7880246189DQ37132068-95371F9A-3F57-4C98-8048-CBF3E6A686EE
P2860
Single-domain antibodies as building blocks for novel therapeutics
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Single-domain antibodies as building blocks for novel therapeutics
@ast
Single-domain antibodies as building blocks for novel therapeutics
@en
Single-domain antibodies as building blocks for novel therapeutics
@nl
type
label
Single-domain antibodies as building blocks for novel therapeutics
@ast
Single-domain antibodies as building blocks for novel therapeutics
@en
Single-domain antibodies as building blocks for novel therapeutics
@nl
prefLabel
Single-domain antibodies as building blocks for novel therapeutics
@ast
Single-domain antibodies as building blocks for novel therapeutics
@en
Single-domain antibodies as building blocks for novel therapeutics
@nl
P3181
P1476
Single-domain antibodies as building blocks for novel therapeutics
@en
P2093
Gholamreza Hassanzadeh Ghassabeh
P3181
P356
10.1016/J.COPH.2008.07.006
P407
P577
2008-10-01T00:00:00Z